21st Annual EUROMEETING 2009 Call for Contributions

MARCH 23-25, 2009 INTERNATIONALES CONGRESS CENTRUM BERLIN, Welcome from the EuroMeeting 2009 Co-Chairs - Barry Burnstead and Dr. Susanne Keitel

Dear Friends and Colleagues,

We have great pleasure in inviting you to participate in three days of discussion, information and networking at the 21st Annual EuroMeeting in Berlin, March 23-25, 2009. Whether your involvement is as a session chair, speaker, tutorial instructor, student, emerging professional, exhibitor, patient representative or attendee, we believe you can play a key role in building on the success of the EuroMeeting and ensuring its place as one of the most important European conferences for the professional involved in drug development.

Berlin was chosen as the EuroMeeting 2009 location not just because of its position at the heart of Europe, but also for its dynamism, accessibility, range of good hotel and cultural options, not to mention the excellent conference facilities at the ICC.

We will be concentrating on building the scientific programme over the coming months. This is an exciting process and we urge you to consider being part of it. Information is available here on how to become a EuroMeeting speaker by submitting a presentation abstract.

We look forward to seeing you in Berlin next year.

Barry Burnstead Director of Standards, i3 Global, UK Barry Burnstead has worked in the pharmaceutical industry for 35 years. Formative years were spent in chemistry, project management and biometrics at SmithKline Beecham. He entered the CRO world in 1991, and a year later with colleagues founded a CRO in Germany and established CRUs in Sweden and the UK. In 1999, he decided to concentrate on consulting and joined Domain Pharma. When Phase Forward acquired Domain, he became global Head of Programme Management. Barry joined i3 Statprobe in August 2006 as Director of Project Management and after one year moved to a central role in leading standards implementation.

Dr Susanne Keitel Director, European Directorate of the Quality of Medicines and Healthcare (EDQM), EU Dr. Susanne Keitel joined BfArM in 1997 after 10 years in pharmaceutical development in industry. In the following 10 years with BfArM, she held, amongst others, the positions of Head of Pharmaceutical Quality and Head of EU, International Affairs. She has been a member of various EU working parties, including QWP, PEG, NtA, and, on an international level, ICH Expert Groups. Since October 2007, Susanne is Director of the Council of Europe’s European Directorate for the Quality of Medicines & HealthCare (EDQM). About the DIA EuroMeeting

The Drug Information Association’s Annual EuroMeeting is global in scope, attracting well over 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organisations, academic research centres, regulatory agencies and health ministries. This convergence affords attendees the opportunity to network with professional colleagues from around the world.

The DIA is a professional association of approximately 18,000 members worldwide who are involved in the discovery, development, regulation, surveillance or marketing of pharmaceuticals or related products. We are committed to the broad dissemination of information on the development of new medicines or generics and biosimilars, with continuously improved professional practice as the goal. The DIA is a financially independent non-profit organisation that funds itself from meeting and membership fees. The voluntary efforts of DIA members and speakers allow the DIA to organise conferences, workshops and training courses and provide publications at a reasonable, competitive cost.

Do you have a question about the EuroMeeting? Contact Dermot Ryan at DIA Europe: [email protected]

About THEME AND TOPICS FOR 2009 - PLEASE USE AS A GUIDE FOR SUBMITTING YOUR ABSTRACT

Theme 1 Theme 6 Theme 11 Auditing and Compliance Medical Device Drug Combination: Optimising Drug Development through Co-Chairs: Gabriele Schwarz, Head, GCP Inspection The Medical Opportunities and Regulatory Sound Methodology Services, BfArM, Germany Challenges of the 21st Century Co-Chairs: Jürgen Kübler, Global Head Integrated Safety Helena Van den Dungen,Head, GCP Inspection Co-Chairs: Andreas Grund, General Manager, & Health Economics Biostatistics, Services,Novartis Pharma Services, GCP-Service, Germany Novartis Pharma AG, Switzerland The Netherlands Sabina Hoekstra-van den Bosch, Senior Advisor, Ministry Robert Hemmings, Statistics Unit Manager, MHRA, UK of Health, Welfare and Sport, The Netherlands Theme 2 Theme 12 Regulatory Controversies Theme 7 Health Economics & Health Technology Assessments and New Challenges Project Management in a Changing Environment What Can We Afford and What Not? Assessing Chair: Kerstin Franzén, Senior Director Worldwide Chair: Suzy de Cordt, Group Leader, What Is Sustainable, Socially Acceptable and Regulatory Policy and Intelligence, Pfizer AB, Sweden Senior Project Manager, Merck Serono, Switzerland Equitable in Supporting Access to Innovation. Co-Chairs: Catarina Edfjäll, Head of Regulatory Affairs Theme 3 Theme 8 Europe, Celgene International SARL, Switzerland Clinical Research Media, Society and Research Wills Hughes-Wilson, Director Health Policy Europe, Increased Complexity by Integration Co-Chairs: Nikos Dedes, Co-chair, Genzyme, Belgium of Real Life Settings Patients' and Consumers' Working Party (PCWP), Carolin Miltenburger, Director Health Economics & Co-Chairs: Norbert Clemens, Head Clinical Development, EMEA, EU Outcomes, i3 Innovus CRS Mannheim GmbH, Germany Yann Le Cam, CEO, EURORDIS, France Alar Irs, Deputy Director, State Agency Medicine, Estonia Theme 13 Theme 9 Preclinical-clinical Interface: Theme 4 Future of Drug Development and Manufacture How to Improve Success in Developing Europe’s Role in Global Innovation Co-Chairs: Barbara Sickmüller, Deputy Director General Innovative Medicines Epidemiology, PV, Risk Management and Association of the German Pharmaceutical Industry, Co-Chairs: Bert Haenen, Toxicologist, Post- authorisation Studies: Germany Organon Schering-Plough, The Netherlands Strategies to Better Protect Public Health Christine Mayer-Nicolai, Senior Regulatory Intelligence Klaus Olejniczak, Scientific Director, BfArM, Germany Chair: Monika Pietrek, MD PhD, MSc, Germany Expert, Merck KGaA, Germany Theme 14 Theme 5 Theme 10 Biomarkers and Personalised Medicine Knowledge Management Impact of Technology and Standards Chair: Michael Zuehlsdorf, Novartis Pharma AG, Chair: John Wise, Senior Director, Informatics, on Drug Development: Switzerland Daiichi Sankyo, UK Now Better, Safer and Faster? Co-Chairs: Peter Stokman, Senior Director Clinical Data Theme 15 Management, Organon Schering-Plough, Generic Medicinal Products The Netherlands Chair: Suzette Kox, Senior Director, Scientific Affairs, Valdo Arnera, General Manager- Europe, EGA, Belgium PHT Corporation, Switzerland THEME OUTLINES FOR 2009

Theme 3 Clinical Research Theme 4 Increased Complexity by Integration of Real Life Settings Europe’s Role in Global Innovation Theme on Epidemiology, PV, Risk Management and Post- Norbert Clemens authorisation Studies: Strategies to Better Protect Public Health Head Clinical Development, CRS Mannheim GmbH, Germany Monika Pietrek Alar Irs MD PhD, MSc, Germany Deputy Director, State Agency Medicine, Estonia • Disease versus Pharmacovigilance Surveillance Systems - How Good is our • Paediatric Trials – Practical Issues Baseline Data?

• Patient Reported Outcomes • EU -Harmonized PV Requirements versus Global PV - Supplement or Contradiction? • Strategy of Clinical Development • Technology Impact on Safer Medicines - Myth or Fact? Embracing EDC and ePRO to Capture and Report SAEs • First in Man Studies • Implications of Global Manufacturing and Process Change • Integrated Session with Patient Representatives • Communication and Collaboration between Regulators, Industry, Patients and Prescribers - How much Progress Has Been Achieved? • Novel Clinical Approaches • Methodological Improvements for Safety Decision Making - An Update on • Multinational Trials in China, Africa and South America Infectious Diseases State of the Art

• Conditional Approval • Non-clinical Testing and its Contribution to Avoid Harm-ACritical Assessment • Special Requirements for the Safety of Biologicals, Combination Products and Biosimilars • The Pediatric Regulation and its Impact on Children’s Health • Performance and Quality Control in PV and RM • Strategies for Monitoring Safety during Development Life-cycle Safety Surveillance Plans THEME OUTLINES FOR 2009

Theme 6 Theme 7 Medical Device Drug Combination: Project Management in a Changing Environment The Medical Opportunities and Regulatory Challenges of the Suzy de Cordt 21st Century Group Leader, Senior Project Manager, Merck Serono, Switzerland Andreas Grund General Manager, GCP-Service, Germany Sabina Hoekstra-van den Bosch Senior Advisor, Ministry of Health, Welfare and Sport, The Netherlands

• Device Legislation for Pharmaceutical Oriented People • Project Manager - Leader or Co-ordinator?

• New and Updated Regulations: How Do They Effect Medical Device Drug • Project Management Tools - A Help or Hindrance? Combinations? • Using Project Management to Improve Quality • How to Develop/Change SOPs for Drug Device Combinations: What Impact Does Device Development Have on a Pharmaceutical Company • How to Capitalise on Knowledge-generated Products • Quality Assurance Systems for Drug Device Combination Manufacturers: Experiences of QA Manager and Auditors • Inspection Findings on Investigational Sites and at the Sponsor of Drug Device Combination Trials • Drug and Device Safety: How to Combine Reporting Requirements • Expanding our Horizons to Deliver Device and Drug Combination Products Successfully to Market • New Developments in Drug Delivery Implants: How much Do They Benefit the Current Cancer Therapy? • Diagnosis-treatment Combinations (Theranostics) and New Inhalation Technologies • Parallels between Pharma 'Quality by design' (ICH 8-9-10) and Device Relevant GHTF Documents • Roundtable: The Spirit of One Team Created from Two Worlds – the Key to Successful Development of Devices/Drug Combination Products. THEME OUTLINES FOR 2009

Theme 8 Theme 10 Media, Society and Research Impact of Technology and Standards on Drug Development: Nikos Dedes Now Better, Safer and Faster? Co-chair, Patients' and Consumers' Working Party (PCWP), EMEA, EU Peter Stokman Yann Le Cam Senior Director Clinical Data Management, Organon Schering-Plough, CEO, EURORDIS, France The Netherlands Valdo Arnera • Understanding and Reversing Erosion of Public Trust in Research General Manager- Europe, PHT Corporation, Switzerland

• Sensational Media Coverage (Risk Communication, Risk Management, • Regulatory Acceptance of eSource, Practical Examples and the New EMEA Science Communication) Guidance in Application

• Transparency • The Need to Integrate External Data (Lab, ECG, ePRO) into the EDC System - What Is Useful and What Is Not? • Information to Patients (Direct to Consumer Information, Medical Communication, Health Literacy, Informed consent for medical practice) • Interactive Web Response System Trials - When Can They Be Used?

• Advanced Therapies • The Loose Ends in EDC and How to Address Them.

• A Look into the Future: What Is on the Horizon after We Managed EDC Properly?

• Data Warehousing: What Is Possible and What Makes Life more Difficult?

• Experience with CDISC Models

• CDISC End-to-end: To What Extent?

• CDISC as an Avenue to Process Improvement THEME OUTLINES FOR 2009

Theme 11 Theme 12 Optimising Drug Development through Sound Methodology Health Economics & Health Technology Assessments - Jürgen Kübler What Can We Afford and What Not? Assessing What Is Global Head Integrated Safety & Health Economics Biostatistics, Sustainable, Socially Acceptable and Equitable in Supporting Novartis Pharma AG, Switzerland Access to Innovation. Robert Hemmings Catarina Edfjäll Statistics Unit Manager, MHRA, UK Head of Regulatory Affairs Europe, Celgene International SARL, Switzerland • Pediatric Populations Wills Hughes-Wilson Director Health Policy Europe, Genzyme, Belgium • Adaptive Designs Carolin Miltenburger • New Regulations Director Health Economics & Outcomes, i3 Innovus

• Safety Planning in Drug Development • Health Economics and Health Technology Assessment in 2009: A More Diverse or More Uniform Landscape? • Long-term Treatment in Progressing Diseases / Assessment of Disease • Access to Innovation: A Role for New Approaches? Progression • Market Access in Europe: How Does Innovation Get to the Patients? • What Can We Learn from Late-stage Failures • Demonstrating Cost-effectiveness in Challenging Situations and when Data Is Limited • State of the Art Signal Detection • Conditional Marketing Authorisations: Managing Health Technology • Biomarkers Assessments in a Conditional Environment • Building HTA into Product Development for Success • Missing Data • Medicines Are about More than Money. Building Social Values into Health Economics • Clinical Trials: The start not the end. Building Integrated Data Sets in a European Context to Meet the Needs • What Does the User Consider Value? Including the Patients’ Voice in Assessments THEME OUTLINES FOR 2009

Theme 13 Preclinical-clinical Interface: How to Improve Success in Developing Innovative Medicines Bert Haenen Toxicologist, Organon Schering-Plough, the Netherlands Klaus Olejniczak Scientific Director, BfArM, Germany

• Use of Imaging in Non-clinical Toxicity Testing: What Is its Value? What about Regulatory Acceptance?

• Non-clinical Evaluation of Hepatotoxicity: Where do We Stand? How Skeptic is Pharmaceutical Industry?

• RNAi Therapeutics Safety and Non-clinical Efficacy Testing and Development

• First-in-Man Studies (updated ICH M3 guideline, timing, inclusion of women, MABEL approach)

• Update on ICH S6 Guideline: Reprotox of Homologue Monoclonals. Is it Useful?

• Update on ICH S6 guideline: Safety Pharmacology and Long-term Tox Testing

• Update on Anticancer Drug Guideline and Non-clinical Requirements. Why Necessary?

• Genotoxicity: Revision of ICH S2 and/or Impurities Guideline (staged TTC approach). Why the Need to Revise? What are Current Industries’ Policies with Respect of Impurity Testing?

• Non-clinical Immunogenicity Testing of Biologicals: What Is its Clinical Relevance? Call for Abstracts - Deadline: Friday, May 2, 2008

How to Submit a Presentation Abstract Abstracts are submitted via the DIA website. Please go to www.diahome.org and click on the EuroMeeting 2009 icon. The closing date for receipt of abstracts is: Friday, May 2, 2008.

The many cultural flavours and facets of Europe provide a contrasting In Berlin, we will take our inspiration from the Reichstag and its perspective to the global drug market. Often aspects of Europe are not concept of transparency. We will strive to bring this transparency to our fully understood by colleagues around the world and the EuroMeeting own diverse activities to increase our mutual understanding and help provides a once-a-year opportunity to explain all! For example, EU define our common goals. The usual broad range of topics will be healthcare regulation operates at both country and continent levels addressed with emphases on any European perspective or the contrasts creating an environment full of complexity and subtlety. However, and that exist between countries and continents engaged in what is some may say despite this, there is a highly successful pharmaceuticals euphemously termed global development. In 2009 we will also expand market together with pioneering drug development activities and fair our healthcare horizons by addressing the field of devices and medical reward. The European Union enlargement has effectively integrated technology. the eastern countries into this market. Successful clinical development has effectively consumed the available patient populations in Western You are invited to submit abstracts for presentations that fall within the Europe and taken full advantage of the new patient populations of the themes and topics (detailed above) and your abstract may in addition eastern countries. There is clear evidence of a willingness to implement suggest a session theme that your presentation could be part of. IT solutions with varied level of success. At the regulatory level, EMEA Consider new concepts and perspectives and be bold, be controversial. has arguably spearheaded the quest for technology solutions with Novelty is encouraged. EudraVigilance and EudraCT databases as examples whilst competent authorities can point to their own successful implementations. As we encounter the disappearance of traditional boundaries, there Accompanying this progress are certain regional complexities that are lies before us the challenge to expand our horizons and work with new being addressed such as patient interests and confidentiality of records, colleagues from unfamiliar disciplines. We should reflect upon the freedom of information and evolving drug-device combination collapse of the Berlin Wall, achieved purely by human endeavour and products. We encourage you to gaze into that crystal ball and predict determination and bring this spirit to the EuroMeeting 2009. the challenges of the next decade, aware of the key role Europe has on the global scene. Be a Poster Presenter

Call for Student Poster Abstracts: Abstracts: Deadline November 21, 2008 • All poster abstracts must be received by Friday, November 21, 2008. Full-time university students, residents and fellows are invited to submit Submit your abstract online by going to www.diahome.org and clicking on abstracts for the Student Poster Session which will take place on Tuesday, the EuroMeeting icon. March 24, 2009 at the EuroMeeting 2009 in Berlin. • Abstracts are limited to 100 words • A student may submit only one abstract A total of EUR 1,800 in prize money will be awarded to student winners • Abstracts may not refer to specific brand names based on the following criteria: • Abstracts should follow a structured format including all of the following: • Bona fide research project objectives, methods, results, conclusions • Specific objectives and hypothesis • Submissions must include complete contact information • Clear methods • Abstracts will be reviewed and authors notified of results by Friday, • Analysis of actual data and results December 12, 2008 • Conclusion Call for Professional Poster Abstracts: A maximum of 20 abstracts will be selected for the student poster Deadline November 21, 2008 presentation. A maximum of 40 abstracts from full-time professionals will be selected for the professional poster presentations to be held on Tuesday, March 24, 2009. Eligibility: Full-time students, residents or fellows at the time of the presentation. Selected professional poster presenters will be required to pay the applicable One author or the author’s designee must attend the EuroMeeting. meeting registration fee and will be responsible for all other meeting expenses. Benefits: • One fully supported registration for the EuroMeeting to include: return Abstracts: flight to Berlin, three nights hotel accommodation and complimentary • All poster abstracts must be received by Friday, November 21, 2008. registration for the EuroMeeting Submit your abstract online by going to www.diahome.org and clicking on • A second complimentary EuroMeeting registration for an accompanying the EuroMeeting icon. person • Abstracts are limited to 100 words • Accepted abstracts will be printed in an early 2009 issue of the Drug • Abstracts may not refer to specific brand names Information Journal • Abstracts should follow a structured format including all of the following: • A total of EUR 1,800 in prize money objectives, methods, results, conclusions • Submissions must include complete contact information • Abstracts will be reviewed and authors notified of results by Friday, December 12, 2008 If you require further information about Student or Professional Posters, please contact Dermot Ryan at DIA Europe: [email protected] Posters What past EuroMeeting delegates had to say about their experience

EuroMeeting 2007 Attendees’ Professional Category “The best bio-pharmaceutical forum available in Europe”

EuroMeeting 2007 Attendees’ Level of Organisational Responsibility

“An excellent opportunity to interact with potential clients and other service providers ”

EuroMeeting 2007 Attendees by Country/Region Exhibit at the EuroMeeting 2009

Showcase your company's product or service to over 3000 drug development professionals at the EuroMeeting 2009 in Berlin.

Join over 240 exhibitors to interact with professionals from the pharmaceutical, biotechnology, devices, government, academia, healthcare delivery and related industries, from over 50 countries.

“The largest European Conference for the clinical development profession” For further information, please contact Phyllis Suter at DIA Europe: [email protected] “A good forum to meet international contacts” or call +41 61 225 51 54 “Primary event for all professionals working in pharma and biotech in Europe” Showcase your company's products and services to more than 3,000 key decision makers - all in the one place, at the one time! Senior-level professionals at the EuroMeeting in Vienna included:

1st Secretary Trade & Investment Corporate Compliance Officer, Vice Director of Postgraduate Education Director, Drug Safety Global Regulatory Strategist Acting Deputy Head of Sector, Scientific President, Global RA and QA Director of Professional Services Director, eRegulatory Development, Global Safety Sr. Manager Advice and Orphan Drugs Corporate Regulatory Affairs Director Director of Sales Global Regulatory Operations Head Clinical Operations Advertising and Medical Information Corporate Vice President Drug Safety Director of Standards Director, European Pharmacovigilance Head Clinical Research and Development Specialist Corporate Vice President Information and Director of the Pharmacy Department Director, Global Pharmacovigilance & Manager Regulatory Affairs Operations Assistant Director - ePRO Biometry Director Oncology and Biotechnology Labelling, Europe Europe Assistant Vice President Biologics & Data Quality Manager Therapeutic Group Director, Global Regulatory Sciences Medical and Regulatory Affairs Director Biotech Dean of Faculty Director Operational Regulatory Affairs Informatics Medical Director Australia & New Zealand Associate Professor, Pharmaceutical Department Head, Paediatrics and Director Pharmacouigilance Director, Informatics Medical Director of Clinical Research Sciences Medical Genetics Director Pharmacovigilance Director, Pharmacovigilance Quality Medical Director, Pharmacovigilance Biomarker and Experimental Medicine Deputy Director, Industrial Relations, Director Pharmacy/Analytic and Inhalation System & Licensing Vaccines Clinical Scientist Regulatory Policy and Intelligence Toxicology Director, Preclinical Affairs Post-Marketing Director Business Development & Regulatory Deputy Director, Pharmacovigilance Director Project Management Director, Preclinical Safety President Pharmaceuticals Europe Affairs Director Director and Head of Microbiology Director QA and Affairs Regulatory QP Director, Pre-Submission Divison, Professor Analytics and Research Business Unit Director, Patient Director Drug Safety & Pharmacovigilance Director QA and Compliance Worldwide Regulatory Affairs Professor in Drug Safety Management Programmes Director European Regulatory Affairs Director Regulatory & Scientific Affairs Director, Product Management Professor of Clinical Pharmacology Cardiovascular Portfolio Leader, European Director Genomics, Office of Clinical Distributor Markets EAME Director, Public Private Partnerships Professor of Pediatrics and Pharmacology Regulatory Affairs Pharmacology, CDER Director Regulatory Affairs Expert Inspector, GCP & Professor of Pharmaceutical Technology Chair in Intellectual Property Law Director Global Labeling Director Regulatory Liaison Pharmacovigilance Professor of Pharmacology/Head of Chairman & CEO Director Global QA R&D / MPS Director Regulatory Policy, Intelligence & Expert Pre-Clinical Advisor Perinatal and Pediatric Chief Clinical Officer & Executive VP Director Global Regulatory Affairs Labeling Regulatory Affairs Expert Statistician Professor, Clinical Pharmacology Chief Development Officer Director Global Regulatory Affairs Director Research Expert, Senior Director Global Professor, Department of Chief Executive Officer Director Global Safety Director Safety Management Pharmacovigilance and Epidemiology Pharmacoepidemiology Chief Medical Officer Director Logistics Solution Director Strategic Regulatory Affairs Global Clinical Project Director Regional Head, Global Medical Writing Chief Medical Officer and Senior Vice Director Market Access, Pricing & Europe Global Director of Medical Information Regional Medical Director President Research and Development Reimbursement Director Submissions Management Global EDM Manager Submission Manager Europe Chief Scientific Officer Director Medical & Regulatory Affairs Director, Advanced Technology Setup Global Head Thesaurus Management Vice President Oncology Chief Statistician Director Medical Affairs International Director, Biometrics Global Head, Cardiovascular Assessment Vice President RA & QA Chief Technical Officer Director Medicine Group, Global Drug Director, Clinical Compliance and Training Group Vice President, Global Regulatory Policy Clinical Affairs - Director Safety and Surveillance Director, Clinical Development Global Head, Clinical Quality Assurance and Operations Clinical Director of Pharmacy Director Non-clinical Statistics Director, Clinical Operations Global Head, Data Management Vice President, Neurosciences, Global Clinical eSolutions Specialist Director of Clinical Quality Management Director, Clinical Research Global Head, Project Management Clinical Safety and Pharmacovigilance Clinical Professor, Clinical Pharmacology, Director of Corporate Strategy, Medical Director, Deputy Qualified Person for Global Manager Clin Ops. Vice President, Pharmacoepidemiology Department of Pediatrics Communications Pharmacovigilance, Global Product Safety Global Medical Director VP, Clinical Quality & Compliance Clinical study Support Director Director of Drug Marketing Authorization Director, Development Planning & Global Medical Writing Director VP, Enterprise Solutions Clinical Trial Manager Director of General Medicine Management Global Operations Business Development VP, Global Regulatory Affairs and Safety Commercial Development Manager, Director of Health Outcomes Europe Director, Discovery Biometrics Manager VP, Nonclinical Safety Project, Safety European Regulatory Affairs Director of Legal & Regulatory Affairs Director, Division of Vigilance Risk Global Pharmacovigilance & Epidemiology Assessments COO & Managing Director Director of Pharmacogenomics Management of Medicines - Europe VP, Project Management Portfolio & Corporate Affairs Manager Director of Pharmacovigilance Director, Document Management Global Quality Manager Planning

Exhibit Networking

Networking Receptions, Other Opportunities Coffee and Lunch Breaks • A Regulators Lunch on Monday is an essential part of the programme for EuroMeeting attendees tell us that the regulators from national agencies and the EMEA. networking opportunities presented by the EuroMeeting are one of the key reasons for • On Tuesday, all attendees get together for a drinks reception on the attending. Each year, the EuroMeeting offers Exhibition Floor. Entertainment provided. numerous opportunities to catch up with existing contacts and to make new ones in a • DIA’s Special Interest Area Communities (SIACs) offer a discipline-specific relaxing setting. All networking events at the global community where members can share experiences and knowledge, EuroMeeting are included in the registration fee: find common ground, and network with others in their fields. SIAC food, beer, wine, non-alcoholic beverages and activities are an integral part of the EuroMeeting and they will organise at entertainment. least one networking opportunity in 2009.

• The EuroMeeting’s Exhibition Floor, with over 250 exhibitors, is a great place to network. All refreshment breaks take place on the Exhibition Jitterbug Reception Floor, so it is easy to meet colleagues and friends.

Monday evening will see DIA rocking and rolling • Patient Representatives are supported each year by DIA to attend the to a networking banquet reception at the Palais EuroMeeting where attendees will have a chance to meet them and listen Am Funkturm. The Palais is one of the largest to their priorities and concerns. and most beautiful ballrooms in Berlin and is a premiere venue for social functions. Located just • New to the pharmaceutical industry? The EuroMeeting offers emerging a short walk from the Convention Centre, it is professionals the chance to meet in a special session. the perfect choice for Monday’s reception. In a well-preserved 1950s interior, from the gilded • Over the past years, DIA Europe has increased the opportunities to attend ceiling to the elegant staircase to the panoramic the EuroMeeting. There will be a specific networking programme for bay windows, the Palais Am Funkturm cannot students at the 2009 EuroMeeting in Berlin. fail to impress. The theme of the reception will be the 1950s with music and dance to fit the theme. The Palais am Funkturm is beside the famous Berlin Funkturm (Radio Tower) completed in 1926. Join us in Berlin

The City At the very heart of Europe, Berlin is a bridge between east and west and over the last few years, has evolved into a major platform for communication and knowledge transfer. Berlin is ranked first among Germany’s best conference locations and is in the international top five. Easily accessible, Berlin has three airports providing flight connections to the whole world with 91 airlines operating flights to Berlin from 157 cities in 49 countries. When in Berlin, one of the most extensive underground and regional train systems of any major city in the world as well as over 1,000 buses and trams will help you get around. If that’s not enough, over 7,000 taxi cabs will take you whenever and wherever you want to go. Berlin can boast an outstanding selection of hotels, with more than 600 available across all categories, offering the largest and most modern selection of accommodation in Europe. Nearly all the major international hotel chains are already here. Berlin is cosmopolitan and open 24 hours a day, 7 days a week. About 1,700 events every day are entertaining people from all over the world. A variety of restaurants from all different kinds of cultures and countries, as colourful and diverse as the city itself, are on offer. Every district, every street corner offers something new and exciting. One thing is certain, Berlin is always changing and it is this dynamism that gives Berlin its special appeal. Comprehensive information on a range of topics, from flying to Berlin to restaurants to beer gardens to sightseeing can be found at the tourist information website: www.visitBerlin.de

The Convention Centre

The Internationales Congress Centrum Berlin (ICC Berlin) ranks among the biggest, most advanced and most successful congress venues in the world. It was designed by architects Ralf Schüler and Ursulina Schüler-Witte. The ICC Berlin is a landmark of postwar German architecture and the model for many new congress centres all over the world. With its 80 halls and rooms seating between 20 and 9,100, its versatile facilities, superb technical installations and comprehensive range of services, ICC Berlin is the perfect choice for any convention.

Berlin The Drug Information Association’s Annual EuroMeeting Providing A Neutral Platform for the Pharmaceutical Industry for the last 20 years

1989 Switzerland 2002 Basel Switzerland

1990 Netherlands 2003 Rome Italy

1991 Amsterdam Netherlands 2004 Prague Czech Republic

1992 Basel Switzerland 2005 Lisbon Portugal

1993 UK 2006 Paris France

1994 Berlin Germany 2007 Vienna Austria

1995 Paris France 2008 Barcelona Spain

1996 Copenhagen Denmark

1997 Düsseldorf Germany 21st Annual EuroMeeting

1998 Nice France 2009 Berlin Germany

1999 The Hague Netherlands

2000 Nice France

2001 Barcelona Spain 2009 is a special year to be in Berlin, marking the 20th anniversary of the fall of the Berlin Wall. The image chosen for Berlin 2009 on the cover reflects this and also reflects the global, diverse ethos of the DIA itself. It is of a Berlin mural by artist Kiddy Citny which is part of the East Side Gallery. The Berlin Wall East Side Gallery is a 1.3km-long section of the wall near the center of Berlin. Approximately 106 paintings by artists from all over the world cover this memorial for freedom and make it the largest open air gallery in the world. The Künstlerinitiative East Side Gallery e.V. is a registered non-profit association whose first purpose is the restoration and preservation of one of the last remains of the Berlin Wall that is still at its historical place.

After "The Wall" was opened in 1989, hundreds of artists from all over the world gathered and transformed the east side of the wall in celebration and reflection of this freedom achieved. With the recognition of its special connection of the past and to the present, an artists initiative was formed to preserve this "gallery" and later won Historical Monument status for the 1.3 kilometer section of the wall, now called the East Side Gallery. The Künstlerinitiative (Artists Initiative) East Side Gallery e.V. also forges a vision of heightened international interest in human rights issues and freedom for peoples everywhere. To support the East Side Gallery, please visit: www.eastsidegallery.com

Kiddy Citny is a musician and fine artist, born in in 1957, grew up in , moved to in 1977, lived in Amsterdam and London (1979), in (1980), Bern (1989/90), (1993/94), and also used a studio in until 2000. Citny is a famous Berlin Wall graffiti artist who began playing cat and mouse with German border guards back in 1985. His work features the themes of love and mutuality, peace and freedom, sensitivity and tenderness, willpower and responsibility. Kiddy Citny communicates complex issues with simple metaphors: "Herzgesichter" [heart-shaped faces], "Welt im Arm" [the world in your arms], "Königskinder" [royal children].

For more information, or to register online, visit www.diahome.org or contact the DIA Europe Customer Service Department: Elisabethenanlage 25, Postfach 4002 Basel, Switzerland • Tel. +41 61 225 51 51 • Fax. +41 61 225 51 52 email: [email protected] • www.diahome.org